Inositol

References

1. ^ a b Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol. (1999)
2. ^ a b c d Colazingari S, et al. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. (2013)
3. ^ a b c d Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. (2013)
4. ^ a b Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study. Eur Rev Med Pharmacol Sci. (2006)
5. ^ Michell RH. The multiplying roles of inositol lipids and phosphates in cell control processes. Essays Biochem. (1997)
6. ^ a b Parthasarathy R, Eisenberg F Jr. The inositol phospholipids: a stereochemical view of biological activity. Biochem J. (1986)
7. ^ a b c d e Kaiser LG, et al. Scyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 Tesla. NMR Biomed. (2005)
8. ^ a b Salloway S, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. (2011)
9. ^ Holub BJ. The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and disease. Adv Nutr Res. (1982)
10. ^ Clements RS Jr, Reynertson R. Myoinositol metabolism in diabetes mellitus. Effect of insulin treatment. Diabetes. (1977)
11. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk Clements RS Jr, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr. (1980)
12. ^ a b c Dang NT, et al. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci Biotechnol Biochem. (2010)
13. ^ Balla T. Phosphoinositide-derived messengers in endocrine signaling. J Endocrinol. (2006)
14. ^ a b c Agranoff BW. Turtles All the Way: Reflections on myo-Inositol. J Biol Chem. (2009)
15. ^ Draskovic P, et al. Inositol hexakisphosphate kinase products contain diphosphate and triphosphate groups. Chem Biol. (2008)
16. ^ Mulugu S, et al. A conserved family of enzymes that phosphorylate inositol hexakisphosphate. Science. (2007)
17. ^ Shears SB. Assessing the omnipotence of inositol hexakisphosphate. Cell Signal. (2001)
18. ^ Irvine RF. Inositide evolution – towards turtle domination. J Physiol. (2005)
19. ^ Irvine RF, Schell MJ. Back in the water: the return of the inositol phosphates. Nat Rev Mol Cell Biol. (2001)
20. ^ a b Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. (2013)
21. ^ a b Shaldubina A, et al. Inositol deficiency diet and lithium effects. Bipolar Disord. (2006)
22. ^ Eisenberg F Jr, Parthasarathy R. Measurement of biosynthesis of myo-inositol from glucose 6-phosphate. Methods Enzymol. (1987)
23. ^ Deranieh RM, et al. Probing myo-inositol 1-phosphate synthase with multisubstrate adducts. Org Biomol Chem. (2012)
24. ^ a b c Asplin I, Galasko G, Larner J. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A. (1993)
25. ^ Kennington AS, et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med. (1990)
26. ^ a b Scioscia M, et al. Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitus. Diabet Med. (2007)
27. ^ a b Baillargeon JP, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. (2006)
28. ^ Baillargeon JP, et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. (2008)
29. ^ Stull AJ, et al. Relationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylation. Metabolism. (2008)
30. ^ Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care. (1996)
31. ^ Coady MJ, et al. Identification of a novel Na+/myo-inositol cotransporter. J Biol Chem. (2002)
32. ^ Ostlund RE Jr, et al. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-{3-3H}inositol. J Biol Chem. (1996)
33. ^ Gullapalli RP. Soft gelatin capsules (softgels). J Pharm Sci. (2010)
34. ^ a b Carlomagno G, et al. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. (2012)
35. ^ a b c Gianfranco C, et al. Myo-inositol in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. (2011)
36. ^ Larner J. D-chiro-inositol–its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. (2002)
37. ^ Sun TH, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. (2002)
38. ^ a b c Yamashita Y, et al. Detection of orally administered inositol stereoisomers in mouse blood plasma and their effects on translocation of glucose transporter 4 in skeletal muscle cells. J Agric Food Chem. (2013)
39. ^ a b c Kofman O, et al. Chronic dietary inositol enhances locomotor activity and brain inositol levels in rats. Psychopharmacology (Berl). (1998)
40. ^ Agam G, et al. High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium. Pharmacol Biochem Behav. (1994)
41. ^ Patishi Y, et al. Differential uptake of myo-inositol in vivo into rat brain areas. Eur Neuropsychopharmacol. (1996)
42. ^ Spector R. Myo-inositol transport through the blood-brain barrier. Neurochem Res. (1988)
43. ^ Kofman O, et al. Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizures. Psychopharmacology (Berl). (1993)
44. ^ Levine J, et al. Inositol treatment raises CSF inositol levels. Brain Res. (1993)
45. ^ Shimon H, et al. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry. (1997)
46. ^ Manji HK, et al. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology. (1996)
47. ^ a b Levine J, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. (1995)
48. ^ Levine J, et al. Follow-up and relapse analysis of an inositol study of depression. Isr J Psychiatry Relat Sci. (1995)
49. ^ a b Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord. (2001)
50. ^ Nemets B, et al. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm. (1999)
51. ^ Levine J, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry. (1999)
52. ^ a b c Inositol 6 g daily may be effective in depression but not in schizophrenia.
53. ^ Zukov I, et al. Premenstrual dysphoric disorder–review of actual findings about mental disorders related to menstrual cycle and possibilities of their therapy. Prague Med Rep. (2010)
54. ^ a b Nemets B, et al. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. World J Biol Psychiatry. (2002)
55. ^ Chengappa KN, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. (2000)
56. ^ Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res. (2010)
57. ^ Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat. (2013)
58. ^ Nierenberg AA, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. (2006)
59. ^ Cohen H, et al. Inositol has behavioral effects with adaptation after chronic administration. J Neural Transm. (1997)
60. ^ Einat H, et al. Chronic epi-inositol has an anxiolytic-like effect in the plus-maze model in rats. Int J Neuropsychopharmacol. (1998)
61. ^ Kofman O, et al. The anxiolytic effect of chronic inositol depends on the baseline level of anxiety. J Neural Transm. (2000)
62. ^ a b Palatnik A, et al. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. (2001)
63. ^ Benjamin J, et al. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder. J Psychiatr Res. (1997)
64. ^ Benjamin J, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry. (1995)
65. ^ Kaplan Z, et al. Inositol treatment of post-traumatic stress disorder. Anxiety. (1996)
66. ^ a b Levine J, et al. CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia. Eur Neuropsychopharmacol. (1994)
67. ^ Levine J, et al. Lack of effect of inositol treatment in chronic schizophrenia. Biol Psychiatry. (1993)
68. ^ Fux M, et al. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. (1996)
69. ^ Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
70. ^ Kofman O, et al. The effect of peripheral inositol injection on rat motor activity models of depression. Isr J Med Sci. (1993)
71. ^ Levine J, et al. Lack of effect of 6 g inositol treatment of post-ECT cognitive function in humans. J Psychiatr Res. (1995)
72. ^ Michaelis T, et al. Identification of Scyllo-inositol in proton NMR spectra of human brain in vivo. NMR Biomed. (1993)
73. ^ Frahm J, et al. Localized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequences. J Comput Assist Tomogr. (1991)
74. ^ Seaquist ER, Gruetter R. Identification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H- and 13C-NMR. Magn Reson Med. (1998)
75. ^ a b Fenili D, et al. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl). (2007)
76. ^ a b McLaurin J, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem. (2000)
77. ^ a b Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. (2007)
78. ^ McLaurin J, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. (2006)
79. ^ Townsend M, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. (2006)
80. ^ Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men.
81. ^ Barak Y, et al. Inositol treatment of Alzheimer’s disease: a double blind, cross-over placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. (1996)
82. ^ Levine J, et al. Inositol treatment of autism. J Neural Transm. (1997)
83. ^ Brosche T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values. Arch Gerontol Geriatr. (2001)
84. ^ a b Maeba R, et al. Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with aging. J Atheroscler Thromb. (2007)
85. ^ Bräutigam C, et al. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis. (1996)
86. ^ Maeba R, Ueta N. Determination of choline and ethanolamine plasmalogens in human plasma by HPLC using radioactive triiodide (1-) ion (125I3-). Anal Biochem. (2004)
87. ^ a b Maeba R, et al. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J Nutr Sci Vitaminol (Tokyo). (2008)
88. ^ Saltiel AR. Second messengers of insulin action. Diabetes Care. (1990)
89. ^ Caro HN, et al. Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liver. Biochem Mol Med. (1997)
90. ^ a b McLean P, et al. Reciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by “push-pull” system. J Biol Chem. (2008)
91. ^ Roche TE, et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol. (2001)
92. ^ Denton RM, et al. The hormonal regulation of pyruvate dehydrogenase complex. Adv Enzyme Regul. (1996)
93. ^ Harris RA, et al. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul. (2002)
94. ^ Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem. (2001)
95. ^ Cohen P. The origins of protein phosphorylation. Nat Cell Biol. (2002)
96. ^ a b Kunjara S, et al. Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes. Mol Genet Metab. (1999)
97. ^ Shashkin PN, et al. Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia. (1997)
98. ^ Larner J. D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work. IUBMB Life. (2001)
99. ^ a b Dugani CB, Klip A. Glucose transporter 4: cycling, compartments and controversies. EMBO Rep. (2005)
100. ^ Farese RV, Sajan MP, Standaert ML. Atypical protein kinase C in insulin action and insulin resistance. Biochem Soc Trans. (2005)
101. ^ Ng Y, et al. Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab. (2008)
102. ^ Randhawa VK, et al. GLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cells. J Biol Chem. (2008)
103. ^ a b Ijuin T, Takenawa T. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP). J Biol Chem. (2012)
104. ^ Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. (1999)
105. ^ Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. (2002)
106. ^ a b c Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. J Neurochem. (2007)
107. ^ Tanti JF, et al. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytes. J Biol Chem. (1996)
108. ^ Kotani K, et al. Requirement for phosphoinositide 3-kinase in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes. Biochem Biophys Res Commun. (1995)
109. ^ Kanai F, et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. Biochem Biophys Res Commun. (1993)
110. ^ Furuichi T, et al. Intracellular channels. Curr Opin Neurobiol. (1994)
111. ^ Iwai M, et al. Molecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variant. J Biol Chem. (2005)
112. ^ Co-expression in vertebrate tissues and cell lines of multiple inositol 1,4,5-trisphosphate (InsP3) receptors with distinct affinities for InsP3.
113. ^ Nakashima N, et al. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J Biol Chem. (2000)
114. ^ Stiles B, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity {corrected}. Proc Natl Acad Sci U S A. (2004)
115. ^ Kurlawalla-Martinez C, et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol. (2005)
116. ^ Wada T, et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity. Mol Cell Biol. (2001)
117. ^ Sasaoka T, et al. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia. (2001)
118. ^ Sleeman MW, et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med. (2005)
119. ^ Ijuin T, Takenawa T. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. Mol Cell Biol. (2003)
120. ^ Ijuin T, et al. Increased insulin action in SKIP heterozygous knockout mice. Mol Cell Biol. (2008)
121. ^ Kong AM, et al. Phosphatidylinositol 3-phosphate {PtdIns3P} is generated at the plasma membrane by an inositol polyphosphate 5-phosphatase: endogenous PtdIns3P can promote GLUT4 translocation to the plasma membrane. Mol Cell Biol. (2006)
122. ^ Taguchi A, et al. Identification of Glypican3 as a novel GLUT4-binding protein. Biochem Biophys Res Commun. (2008)
123. ^ Kawa JM, Taylor CG, Przybylski R. Buckwheat concentrate reduces serum glucose in streptozotocin-diabetic rats. J Agric Food Chem. (2003)
124. ^ Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharmacol. (2000)
125. ^ a b Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives.
126. ^ Giordano D, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. (2011)
127. ^ a b Santamaria A, et al. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. (2012)
128. ^ a b c Corrado F, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. (2011)
129. ^ a b D’Anna R, et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. (2012)
130. ^ Chau JF, et al. Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB J. (2005)
131. ^ Grant PS, Lipscomb D. How often do we ask about erectile dysfunction in the diabetes review clinic? Development of a neuropathy screening tool. Acta Diabetol. (2009)
132. ^ Hecht MJ, et al. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res. (2001)
133. ^ a b c d Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. (2003)
134. ^ a b c d Genazzani AD, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. (2012)
135. ^ a b Donà G, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. (2012)
136. ^ a b Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. (2012)
137. ^ Gerli S, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. (2007)
138. ^ a b c Carmina E. PCOS: metabolic impact and long-term management. Minerva Ginecol. (2012)
139. ^ Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. (2009)
140. ^ Broekmans FJ, et al. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. (2006)
141. ^ Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guide. Drugs. (2006)
142. ^ Cascella T, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. (2008)
143. ^ Ciampelli M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. (1999)
144. ^ Metformin in polycystic ovary syndrome: systematic review and meta-analysis.
145. ^ Unfer V, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. (2012)
146. ^ a b c d Artini PG, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. (2013)
147. ^ a b c Costantino D, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. (2009)
148. ^ Genazzani AD, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. (2008)
149. ^ a b Papaleo E, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. (2007)
150. ^ Ciotta L, et al. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. (2011)
151. ^ Lisi F, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol. (2012)
152. ^ Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. (2010)
153. ^ Hazell AS, Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanisms. Proc Soc Exp Biol Med. (1999)
154. ^ Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab. (1991)
155. ^ Shawcross DL, et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol. (2004)
156. ^ Lien YH, et al. Scyllo-inositol depletion in hepatic encephalopathy. Life Sci. (1994)
157. ^ Binesh N, et al. Hepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological study. J Appl Clin Med Phys. (2006)
158. ^ a b Wattenberg LW, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis. (2000)
159. ^ Hecht SS, et al. Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo. Cancer Lett. (2001)
160. ^ Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzo{a}pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis. (1993)
161. ^ a b c Lam S, et al. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. (2006)
162. ^ Zacchè MM, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. (2009)
163. ^ a b Skoven I, Thormann J. Lithium compound treatment and psoriasis. Arch Dermatol. (1979)
164. ^ a b Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. (2000)
165. ^ a b Williams RS, et al. A common mechanism of action for three mood-stabilizing drugs. Nature. (2002)
166. ^ a b The effect of inositol on lithium-induced polyuria—polydipsia in rats and humans.
167. ^ a b c Allan SJ, et al. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. Br J Dermatol. (2004)
168. ^ Cupisti S, et al. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS. Exp Clin Endocrinol Diabetes. (2007)
169. ^ Mueller A, et al. Endocrinological markers for assessment of hyperandrogenemia in hirsute women. Horm Res. (2007)
170. ^ Minozzi M, D’Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online. (2008)
171. ^ Smith DF. Lithium orotate, carbonate and chloride: pharmacokinetics, polyuria in rats. Br J Pharmacol. (1976)
172. ^ Minozzi M, et al. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol. (2011)
173. ^ Galletta M, et al. Bye-bye chiro-inositol – myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction. Eur Rev Med Pharmacol Sci. (2011)
174. ^ Isabella R, Raffone E. Does ovary need D-chiro-inositol. J Ovarian Res. (2012)
175. ^ Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesions. Anticancer Res. (2003)
176. ^ Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. Life Sci. (1997)
177. ^ Singh RP, et al. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res. (2004)
178. ^ Bohn T, et al. Phytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humans. Am J Clin Nutr. (2004)
179. ^ Larsson M, et al. Improved zinc and iron absorption from breakfast meals containing malted oats with reduced phytate content. Br J Nutr. (1996)
180. ^ Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr. (2003)
181. ^ Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer. (2006)
182. ^ Tantivejkul K, et al. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. Breast Cancer Res Treat. (2003)
183. ^ a b Bacić I, et al. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J Exp Clin Cancer Res. (2010)
184. ^ Unfer V, et al. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. (2011)
185. ^ a b Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. (2010)
186. ^ Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. (2011)
187. Unfer V, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. (2011)
188. Iuorno MJ, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. (2002)
189. Papaleo E, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. (2009)